The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABSI | +3.89% | N/A | N/A | -80% |
| S&P | +16.9% | +95.99% | +14.39% | +56% |
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.59M | -53.3% |
| Gross Profit | -$2.41M | -13.9% |
| Gross Margin | -405.90% | -239.4% |
| Market Cap | $327.83M | -5.9% |
| Market Cap / Employee | $2.09M | 0.0% |
| Employees | 157 | 0.6% |
| Net Income | -$30.57M | -23.5% |
| EBITDA | -$28.39M | -21.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $54.23M | -8.8% |
| Accounts Receivable | $0.70M | 1490.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.71M | -55.7% |
| Short Term Debt | $3.70M | -25.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.69% | -12.5% |
| Return On Invested Capital | -39.25% | -2.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17.10M | 0.5% |
| Operating Free Cash Flow | -$16.87M | -0.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.96 | 1.49 | 1.62 | 1.65 | 13.75% |
| Price to Sales | 103.16 | 66.15 | 64.88 | 79.24 | -25.96% |
| Price to Tangible Book Value | 2.48 | 1.92 | 2.16 | 2.12 | 17.27% |
| Enterprise Value to EBITDA | -11.87 | -6.85 | -6.95 | -7.10 | -16.88% |
| Return on Equity | -49.1% | -58.0% | -49.0% | -57.4% | 35.86% |
| Total Debt | $11.99M | $10.11M | $8.92M | $7.41M | -44.40% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
